Introduction
============

Cross-country and inter-institutional research collaborations are progressive developments in an increasingly globalized and interdependent world. However, the improvements in governance and policies surrounding distribution and use of research articles, databases and data collection tools have lagged behind. The need for socially responsible licensing policies for access to data and tools highlights the growing commercialization of the products of research. We can contrast this with universities' and public health organizations' goals of contributing to the public interest. Commercialization often leads to patents and intellectual property management becoming restrictive for research and product use in low- and middle-income countries. For example, a university-developed, but privately funded research on a drug or formulation may result in a patent that belongs to the private entity; without appropriate licensing strategies, the private entity may register the drug in many countries, which could result in limited access to the drug in resource-constrained settings. Research may also be concentrated on areas that are more beneficial to funders, as opposed to areas that would address issues for disadvantaged communities or settings.[@R1] Furthermore, paywalls, such as charges for accessing journal articles, can hinder the flow of scientific information and developments that rely and build on previous research.[@R2] A worrying trend is organizations charging for access to research tools and databases that are vital to research supporting national and international policy development.

Research consortia in the United Kingdom of Great Britain and Northern Ireland and the United States of America routinely restrict access to their economic models or global health estimates.[@R3] The website of United States National Guideline Clearinghouse, which housed more than 2000 easily and freely accessible guidelines for evidence-based health care, was taken down in July 2018 due to government budget cuts.[@R4] The Cochrane Library, which is a repository of high-quality research to support health care decision-making globally, allows only one-time access before requiring payment, even for researchers from low- and middle-income countries.[@R5] These research tools and databases are becoming increasingly hard to access. Barriers to information access are especially problematic for governments and researchers in low- and middle-income countries, who often contribute their own resources towards further development of these products. Given the importance of standard tools for supporting country and global priority-setting, research and development, it is important to examine barriers to their access.

One example of this issue is the case of the EuroQol-five-dimensional questionnaire (EQ-5D; EuroQol Group, Rotterdam, Netherlands), a tool for measuring health status. EuroQol Group is managed by the not-for-profit EuroQol Research Foundation, which owns the intellectual property rights to EQ-5D in Europe, North America and other parts of the world. In November 2018, a lawyer from the Foundation approached a researcher from the Thai Health Intervention and Technology Assessment Program to provide evidence of use of the EQ-5D tool in Thailand as support for registering the tool as a trademark. After a few exchanges, it became clear that EuroQol aimed to register the EQ-5D under a new policy that could result in potentially charging users of the tool in Thailand. Arguably, the charge was reasonable for commercial use of EQ-5D, but this new policy, dated June 2018, meant that noncommercial, nonresearch use was also to be explicitly charged.[@R6] All countries, even low-income countries, would be asked to pay this charge. Following complaints by the Thai Health Intervention and Technology Assessment Program, EuroQol agreed to reconsider the policy and, in January 2019, reversed their decision.[@R7]^,^[@R8]

An important noncommercial, nonresearch use of the EQ-5D is the routine collection of patient-reported outcome measures in clinical settings. Such data form part of many health systems' monitoring efforts to improve service quality and inform patient choice of providers. In this paper we share a brief history of licensing for the EQ-5D with the aim of informing the global health community and encouraging discussion about the development and management of similar research tools. The paper is also a call for more sharing of research tools such as executable models and databases as well as guidelines and best practice norms that have the potential to inform global and national health policies.

EQ-5D and the global community
==============================

The EQ-5D tool is a generic measure of health status within five dimensions (mobility, self-care, usual activities, pain or discomfort, anxiety or depression) on three levels (no problems, some problems, extreme problems). The tool's origins lie in academic papers published in the 1970s and 1980s.[@R9]^--^[@R13] EuroQol developed the tool in the 1980s to measure, value and compare health status across disease areas, primarily with the aim of using the results to inform resource allocation decisions. EuroQol's objectives were to develop a standardized instrument for measuring health-related quality of life, which had dimensions relevant to a broad range of patients, as well as to the general population and, which would be simple and easy to complete.[@R14] The reliability and validity of the tool was tested on a variety of populations and patients, and research continues on issues, such as the effect of the duration of the health states on patients' self-reported values and other considerations, for example the use of the tool in large-scale health-system applications. EuroQol has also published EQ-5D-5L, a more sensitive tool that includes more levels (no problems, slight problems, moderate problems, severe problems, extreme problems) and EQ-5D-Y, a tool for measuring children's and adolescents' health status.[@R14]

The EQ-5D is the most frequently used tool for generating quality-adjusted life years values. These values are applied as health outcomes in economic evaluations, a type of health technology assessment. Use of the tool grew markedly with the increasing application of health technology assessment for decision-making through the National Institute for Health and Care Excellence in the United Kingdom and similar institutions in other countries. Pharmaceutical companies included EQ-5D in their health technology assessment submissions, paying fees for its use and providing EuroQol with a revenue source. This revenue allowed EuroQol to have formalized legal arrangements, establish the EuroQol Group and Foundation and to create a business model to facilitate not-for-profit research activities.

All users are now required to register the instrument (copyright belongs to the EuroQol Group). Only commercial, for-profit users were charged. Over time, group membership became an international network. The EuroQol Foundation has since developed procedures for ensuring that cultural adaptations of the tool retain the intended meaning of the original and a protocol for assigning valuations to ensure standardization.[@R11]^,^[@R14] The protocol is a standard method to assess health state preferences, ensuring that the valuations remain consistent across countries with different cultures and social and economic status.

The Foundation now provides leadership in the development of instruments for describing and valuing health, promoting the use of these tools, fostering support for the international community of researchers developing these tools and ensuring the proper use of the tools in the various contexts in which they are applied. The ease and simplicity of use of the EQ-5D have allowed it to be incorporated in clinical trials, observation studies, population health surveys and patient-reported outcome measures.[@R11]^,^[@R14]

EuroQol has promoted and supported EQ-5D use and development for research in many countries through educational and uptake initiatives. Similarly, these efforts received support from the research community globally in testing and developing local values to allow translation from EQ-5D scores to health utilities that are used in economic evaluations.[@R14] For example, in 2004, the Thai Health Intervention and Technology Assessment Program used public resources to fully fund a household survey for assessing the Thai valuation of EQ-5D-3L.[@R15] In 2007, the Thai health technology assessment guideline endorsed the use of EQ-5D as the preferred health utility measure for economic evaluations conducted for allocating health resources by the Thai government,[@R16] one of the first low- and middle-income countries to do so. The second household survey to assess the Thai value set of EQ-5D-5L was also partially supported through Thai government funds.[@R17]

It is clear that, from the very beginning and throughout its subsequent development, the EQ-5D has been created and extended by researchers employed in public institutes, supported by public research funding and used in the formation of public policy.

Are charges appropriate?
========================

There can be advantages to charging for use of the EQ-5D. Charging enables the monitoring of the tool's use and so maintains consistency in its meaning and use. Charges can also be used to build up reserves for supporting further research, developing the tool and promoting its use in research and clinical practice. Furthermore, charges fund EuroQol staff who receive applications for translation and use, respond in a timely manner to questions and organize conferences and meetings with various stakeholders to learn about the tool and its applicability in diverse settings.[@R14] The staff members also ensure that an appropriate version of the tool is used that fits the research goals of each applicant.[@R11] More countries are now inviting pharmaceutical companies to submit or conduct studies that require the use of the EQ-5D, which means there is greater potential for income generation in that area.

We believe, however, that charging should only be for commercial use of the tool. Noncommercial use of EQ-5D should remain free of charge and it is encouraging that the foundation reconsidered its charging policy.[@R6]^,^[@R8] Since the tool was an outcome measure developed in universities for public policy purposes, it is inappropriate for those same universities and similar non-profit public agencies to be charged for its use. EQ-5D increases in value with continued use by governments and academics.[@R18]^--^[@R22] This development might not have occurred if the charging policy had been outlined beforehand, because the process for the tool's development has involved the sharing of resources supported by governments and many academics.

Patient-reported outcome measures are an important component of policy assessment and review. As the EQ-5D is a simple tool that is easy to complete, it is a good measure of patient-reported outcome measures with an accepted role in clinical settings for diagnosing and monitoring disease progression and patients' health status; for facilitating communication and shared decision-making with patients; and for gathering data on the effects of interventions. Patient-reported outcome measures are reliable predictors of disease progression to complement traditional indicators (such as tumour markers or tumour response)[@R23]^,^[@R24] and help doctors, governments and relevant stakeholders to meet the demands and needs of their patients more effectively. Such measures are especially needed by countries and health systems in their journey towards universal health coverage.

Many clinics, hospitals and government health systems in low-income countries would likely be unable to afford the user charges. Even middle-income countries that could theoretically afford to pay charges may have more pressing demands on their health research budgets. The United Kingdom currently uses the EQ-5D tool for its national programme of patient-reported outcome measures,[@R25] with many countries following suit. Charging for use of the tool could eventually disincentivize its use. Governments, particularly in low- and middle-income countries with greater resource constraints, could disinvest or commit fewer resources to tools with such barriers, perhaps jeopardizing efforts to develop the EQ-5D in countries that could benefit most from its use. The loss of investment in research development needs to be balanced against the revenue gains from charging.

Finally, the measurement of quality-adjusted life years has been promoted globally and endorsed by health technology assessment agencies, such as the National Institute for Health and Care Excellence, National Institute for Health Research and Thai Health Intervention and Technology Assessment Program.[@R26]^--^[@R28] The understanding among agencies was that the tools to measure quality-adjusted life years would be freely accessible. EuroQol is laudable for providing the questionnaire free of charge for such purposes. This practice contrasts with the health utilities index of Health Utilities Inc.[@R29] or the six-dimensional health state short form (SF-6D) of the University of Sheffield,[@R30] which have charges or financial barriers for noncommercial research use. The SF-6D, for example, allows a one-study use for non-profit and research organizations and charges subsequent studies. As in Thailand, other low- and middle-income countries are investing in the EQ-5D value sets for this reason ([Fig. 1](#F1){ref-type="fig"}). However, changing the policy sets a precedent for future charges for other EQ-5D uses that could restrict the use of the quality-adjusted life years measure on a global level.
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Policy questions
================

There are several policy-relevant questions we can pose to research agencies who are developing tools for global use when considering sustainable models of income generation. First, is it justifiable to charge for the tools needed to measure key global health indicators? Second, is it justifiable to differentiate between commercial and noncommercial uses of the tools and charge only for the former? Third, is it justifiable to differentiate between research and nonresearch uses of the tools and charge only for the latter? Fourth, do not-for-profit groups need top-up funding to supplement the revenues which they currently generate? Fifth, are there any circumstances in which it would be acceptable to charge noncommercial research users for use of these tools? Sixth, what are the best methods for informing users and keeping them up-to-date with policy changes regarding charges for use of these tools? Finally, is there a consensus concerning the answers to these questions?

Ensuring information and research accessibility
===============================================

We need to look at how to sustain high-quality research efforts while ensuring accessibility to the products and tools of such research. EuroQol's change in policy is part of a pushback against barriers to information access, especially concerning information generated by publicly funded research. These responses include initiatives such as the Tufts Cost-effectiveness Analysis Registry and the F1000Research database that invite researchers to upload their models and papers to be freely available; the Bill and Melinda Gates Foundation and the Wellcome Trust adopting open-access policies to ensure that their funded research is accessible; and calls to allow transparency through the All Trials Campaign, an initiative that aims to have all results and methods from previous and current clinical trials registered and reported.[@R35]^--^[@R39]

Another promising initiative is socially responsible licensing, which allows licensing of technologies and medicines for defined populations to provide differential access or prices compared with regular licensing policies.[@R40] Socially responsible licensing includes different licensing strategies with the end goal of safeguarding access. For example, universities in the United States of America have begun implementing these licences by defining the contractual language to ensure royalty-free or reduced fees for specific purposes or for use by low- and middle-income countries or humanitarian groups. The initiative has generated even more research. A positive development from these policies was the stimulation of the support and investment from licensees and philanthropic organizations to universities.[@R40]^,^[@R41] Socially responsible licensing has the potential to reduce barriers to information access and research development for low- and middle-income countries, while still ensuring the sustainability, quality and development of global research and tools.
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The Thai government supported the development of the local EQ-5D value set, and its national guidelines endorse the use of the tool in health economic evaluation. However, the charging policy for non-commercial, non-research use will have no financial effect on Thai Health Intervention and Technology Assessment Program and the co-authors.
